Developer docs
API playgroundTry for free, no card

Search company profiles

IVERIC bio

Full company profile

uuid0004vzm

Namestring
IVERIC bio
Legal namestring
Iveric Bio
Websiteurl
ivericbio.com
Company typeenum
Public
Founded yearint
2007
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ophthalmic therapeutics, retinal disease drugs, complement inhibitors, age-related macular degeneration, biopharmaceutical products
Industry3 codes
1Ophthalmology Pharmaceuticals
CodeHLAIAAALPrimaryYes
2Ophthalmology Specialty Pharmaceuticals
CodeHLAIACAKPrimaryNo
3Retina & Vitreous Specialists
CodeHLAKAKAEPrimaryNo
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of prescription pharmaceutical products, specifically Zimura (avacincaptad pegol) for geographic atrophy. The company prepared for commercial launch contingent on FDA approval, targeting the U.S. market through specialty pharmacy and physician administration channels.

investors.ivericbio.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IVERIC bio developed Zimura (avacincaptad pegol), a novel complement C5 inhibitor administered via intravitreal injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug targets the complement pathway to reduce photoreceptor degeneration and slow progressive, irreversible vision loss. IVERIC bio was preparing for commercial launch of Zimura in the United States, contingent on FDA regulatory approval.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Iveric Bio was a pharmaceutical company focused on developing Zimura, an investigational drug for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The company pursued regulatory approval for Zimura in the United States with plans for commercial launch, funded in part by debt financing agreements. As of the available source data, Iveric Bio has been acquired by Astellas Pharma Inc.

Product and service1 record
1Zimura (avacincaptad pegol)
CategoryOphthalmic Biopharmaceuticals
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IVERIC bio

Ophthalmic Biopharmaceuticalsivericbio.com

IVERIC bio firmographics

Firmographics
Name
IVERIC bio
Legal name
Iveric Bio
Website
https://ivericbio.com
Company type
Public
Founded year
2007
Operating status
Acquired
Headcount range
101–250 employees
Ownership category
akta.pro rank

IVERIC bio industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Ophthalmology Pharmaceuticals (HLAIAAAL)
akta.pro secondary industries
Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Retina & Vitreous Specialists (HLAKAKAE)

Keywords

  • Ophthalmic therapeutics
  • Retinal disease drugs
  • Complement inhibitors
  • Age-related macular degeneration
  • Biopharmaceutical products

Where IVERIC bio is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Markets served

IVERIC bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of prescription pharmaceutical products, specifically Zimura (avacincaptad pegol) for geographic atrophy. The company prepared for commercial launch contingent on FDA approval, targeting the U.S. market through specialty pharmacy and physician administration channels.

Go-to-market motion1 record

Distribution channels1 record

IVERIC bio product offering

Product offering

Core offering

IVERIC bio developed Zimura (avacincaptad pegol), a novel complement C5 inhibitor administered via intravitreal injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug targets the complement pathway to reduce photoreceptor degeneration and slow progressive, irreversible vision loss. IVERIC bio was preparing for commercial launch of Zimura in the United States, contingent on FDA regulatory approval.

Product overview

Iveric Bio was a pharmaceutical company focused on developing Zimura, an investigational drug for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The company pursued regulatory approval for Zimura in the United States with plans for commercial launch, funded in part by debt financing agreements. As of the available source data, Iveric Bio has been acquired by Astellas Pharma Inc.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zimura (avacincaptad pegol)

Companies that use IVERIC bio

Customer profile

Segments1 record

Ideal customer profiles1 record

IVERIC bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

IVERIC bio partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

IVERIC bio competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

IVERIC bio social profiles

Digital presence

IVERIC bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IVERIC bio leadership team

Management profile

Number of profiles

Profiles9 records

IVERIC bio funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IVERIC bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVERIC bio

What does IVERIC bio do?

IVERIC bio developed Zimura (avacincaptad pegol), a novel complement C5 inhibitor administered via intravitreal injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug targets the complement pathway to reduce photoreceptor degeneration and slow progressive, irreversible vision loss. IVERIC bio was preparing for commercial launch of Zimura in the United States, contingent on FDA regulatory approval.

Is IVERIC bio a public or private company?

IVERIC bio is a public company. It is classified as corporate owned and is currently acquired.

When was IVERIC bio founded?

IVERIC bio was founded in 2007. It employs 101 to 250 people.

Where is IVERIC bio based?

IVERIC bio is headquartered in Princeton, United States, in the North America region.

How does IVERIC bio make money?

One revenue line is on record: pharmaceutical Product Sales.

Does IVERIC bio have an API?

No public API is recorded for IVERIC bio.

What industry is IVERIC bio in?

IVERIC bio's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Phirda小核酸药物递送技术的演进 ——从肝脏靶向到肝外递送Small nucleic acid drug delivery has shifted from liver-targeted GalNAc and LNP to extrahepatic routes like muscle, CNS, and kidney. GalNAc drugs such as inclisiran and eplontersen have been approved, but extrahepatic delivery faces challenges like low dystrophin expression in DMD. Future strategies include AOC, peptide conjugates, and lipid conjugates to expand beyond the liver.Ophthalmology TimesHigh-resolution multimodal imaging is key in dry AMD therapeutic development, future managementInvestigators are exploring multiple strategies to combat dry age-related macular degeneration (AMD), particularly using high-resolution optical coherence tomography (OCT) for monitoring disease progression. Notable compounds in development include pegcetacoplan from Apellis Pharmaceuticals and Zimura from Iveric Bio, with promising results in clinical trials noted for therapies targeting inflammation and oxidative stress. The advancements in OCT technology enhance the ability to track treatment efficacy and disease markers, underscoring the importance of these innovations in future management.Labiotech.euBiotech in New Jersey: Nine companies leading the chargeThe article highlights nine biotech companies in New Jersey, detailing their therapeutic pipelines, recent funding rounds, and regulatory milestones. Key developments include Iveric Bio receiving FDA approval for Zimura and LEO Pharma acquiring Timber Pharmaceuticals to expand its dermatology portfolio.PR NewswireAstellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyIveric Bio, an Astellas Company, announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent Healthcare Common Procedure Coding System J-code (J2782) for IZERVAY, effective April 1, 2024. The permanent J-code is expected to streamline billing and reimbursement processes for the geographic atrophy treatment, accelerating patient access in the U.S. market where more than 40,000 vials have been distributed since the drug's launch in September 2023.PR NewswireTwo-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)Iveric Bio, an Astellas company, announced a partnership with two-time Emmy Award-winning actor Eric Stonestreet to raise awareness about geographic atrophy (GA), a form of age-related macular degeneration causing irreversible vision loss. Eric and his mother, Jamey, are sharing their family's experience with GA and AMD to encourage people to learn about the disease and prioritize eye health as part of the 'More to See' campaign. GA affects approximately 1.5 million people in the United States, with only one in four people diagnosed.PR NewswireEuropean Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic AtrophyThe European Medicines Agency has accepted the marketing authorization application for avacincaptad pegol, an investigational treatment for geographic atrophy secondary to age-related macular degeneration. The review will be conducted by the Committee for Medicinal Products for Human Use under the centralized licensing procedure covering all 27 EU member states. This development follows the drug's recent approval in the United States and represents a key regulatory milestone for Astellas Pharma Inc. and its subsidiary Iveric Bio.PR NewswireAstellas Completes Acquisition of Iveric BioAstellas Pharma Inc. has completed the acquisition of IVERIC bio, Inc., making it a wholly-owned subsidiary following shareholder and regulatory approvals on July 11, 2023. The transaction was valued at approximately US$5.9 billion, or US$40 per share, marking a significant expansion into ophthalmology for Astellas. This move positions both companies to potentially lead in the development and commercialization of treatments for retinal diseases, such as geographic atrophy.PR NewswireGeographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric BioDelveInsight published a market insights report projecting the geographic atrophy market to grow significantly at a substantial CAGR during 2019–2032, with approximately 3 million prevalent cases across the 7MM in 2021. In February 2023, the FDA approved SYFOVRE (pegcetacoplan injection) by Apellis Pharmaceuticals as the first and only FDA-approved therapy for geographic atrophy, while also granting priority review to Iveric Bio's Zimura (avacincaptad pegol) with a PDUFA goal date of August 2023. Key market drivers include improving diagnosis methodologies, disease awareness, and incremental healthcare spending, though growth may be tempered by lack of validated endpoints, clinical trial failures, and reimbursement challenges.The Pharma LetterThe Pharma Letter M&A roundup - May 2023Biopharma M&A activity in May 2023 was characterized by significant spending from smaller drugmakers and reverse mergers, with Astellas acquiring Iveric Bio as a notable deal. Overall 2023 spending remains elevated compared to previous years, largely driven by Pfizer's $43 billion acquisition of Seagen announced in March.PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.Weiss Law is investigating possible breaches of fiduciary duty by the board of directors of IVERIC bio, Inc. in connection with the company's proposed acquisition by Astellas Pharma Inc. Under the merger agreement, IVERIC shareholders will receive $40.00 in cash per share, valuing the transaction at approximately $5.9 billion. The law firm is examining whether the board acted in shareholders' best interests and whether the merger consideration adequately compensates them.